{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-017879","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2025-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.399083+00:00","generated_at":"2026-05-26T23:25:55.904499+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CRISPR Therapeutics Q4 net loss $37.3M; cash at $1.9B; 50+ ATCs activated","bullets":["Q4 2024 net loss of $37.3M vs net income of $89.3M in Q4 2023.","Cash, cash equivalents, and marketable securities of $1,903.8M, up from $1,695.7M a year earlier.","Over 50 authorized treatment centers activated globally for CASGEVY; >50 patients have had cells collected.","R&D expenses fell to $82.2M in Q4 2024 from $95.1M in Q4 2023.","Pipeline catalysts in 2025: CTX112 updates mid-2025; CTX310/320 updates H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-017879","json":"https://secwatch.observer/filing/0000950170-25-017879.json","markdown":"https://secwatch.observer/filing/0000950170-25-017879.md","text":"https://secwatch.observer/filing/0000950170-25-017879.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000095017025017879/0000950170-25-017879-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000095017025017879/crsp-20250211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:25:55.904499+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}